Melinda A Pruis

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Tyrosine Kinase

Advanced Non Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

JCO precision oncology

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Melinda A Pruis, Matthew G Krebs, Ruth Plummer, Filip Yves Francine De Vos, Eric Angevin, Hans Prenen, Martin D Forster, Glen Clack, Annegret Van der Aa, Marc Tjwa, Ellen Jansen, Timothy Perera, Martijn Paul Lolkema
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. The oncologist (2023)
Melinda A Pruis, M S Paats, W R R Geurts, Hendrikus Jan Dubbink, Anne-Marie C Dingemans
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation. JCO precision oncology 5 (2022)
Melinda A Pruis, Floris H Groenendijk, K Sangeeta Badloe, Andrea van Puffelen, Debbie G J Robbrecht, Winand N M Dinjens, Stefan Sleijfer, Anne-Marie C Dingemans, Jan H von der Thusen, Paul Roepman, Martijn Paul Lolkema
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British journal of cancer 127 (4) (2022)